PLGA (Poly(lactic-co-glycolic acid))

This document is technical information about materials. It does not recommend any procedure or product.

In brief

A copolymer of lactic and glycolic acid, widely used in resorbable medical products. In aesthetics the application described in the literature is the resorbable thread rather than the injected particulate biostimulator.

Regulatory identity by market

KR MD
EU MD
US
JP
CN
VN

COS cosmetic · MD medical device · RX drug · — not established in public sources

Identity & physical properties
SynonymsPoly(lactic-co-glycolic acid), Poly(lactide-co-glycolide), PLGA, PGLA
FamilyAliphatic polyester copolymer
Particle sizeDepends on the form — fibres, microparticles and nanoparticles are all described; no single figure characterises the material
MorphologySupplied as fibres and threads, as microparticles, or as nanoparticles, according to application
Molecular weightVaries by grade. The lactide-to-glycolide ratio, not molecular weight alone, drives the reported breakdown rate

Mechanism

Hydrolytic breakdown to lactic and glycolic acid monomers, with the copolymer ratio governing the rate. Aesthetic literature describes the material in resorbable suspension threads; injectable particulate forms appear in tissue-engineering work, where fibres have been reported to support adipose graft retention.

Evidence

PMIDStudy typeSummary
32440186 review Review of combined minimally invasive facial treatments, describing PLGA in a resorbable suspension thread alongside PCL- and PLLA-based materials
37326365 in vivo Injectable pulverised electrospun PLGA fibres reported to improve human adipose tissue engraftment and volume retention
38173050 review Review of PLGA nanoparticles for transdermal drug delivery
37409477 in vitro Degradation behaviour of PLGA scaffolds measured in phosphate buffered saline

Regulatory identity — detail

MarketClassificationNoteBasis
KR medical-device Resorbable thread and suture products follow the device route in the MFDS classification notice. This is the form in which the copolymer is established in aesthetic practice. Legal text
EU medical-device Falls under the MDR. Note the difference from the injectable biostimulators on this site: Annex XVI covers substances introduced by injection for filling, whereas thread products are handled under the general provisions of the Regulation. Legal text
US unclassified As of the revision date below, the full set of FDA premarket approval records listed under the generic name 'implant, dermal, for aesthetic use' was reviewed (22 distinct approvals), and a PLGA dermal implant was not found in that list. Listing through a route outside this generic name cannot be ruled out, so this is left unestablished.
JP unclassified Not established from public sources as of the revision date below.
CN unclassified Not established from public sources as of the revision date below.
VN unclassified Not established from public sources as of the revision date below.

Limitations & open questions

A literature search for randomised trials of injected particulate PLGA in facial aesthetic indications returned none as of the revision date below; the aesthetic evidence base describes thread applications, and the injectable work is preclinical. The lactide-to-glycolide ratio changes the breakdown rate substantially, so a duration quoted for one grade does not describe the copolymer family. PGLA is an alternative ordering of the same name and is not a different material.

All statements on this page are drawn from the cited literature. Where a market’s regulatory classification could not be established from public sources, it is marked as not established rather than inferred.

PLGA is often grouped with the lactic-acid polyesters elsewhere in this atlas, and chemically that grouping holds. The published aesthetic use differs: PLLA and PDLLA appear as injected particulate materials, while PLGA appears in resorbable threads. When a claim about PLGA is transferred from one form to the other, check whether the underlying study used the same form.